A PHASE III DOUBLE-BLINDED MULTICENTER RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER
Brief description of study
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a combination of either nab-paclitaxel with carboplatin, pemetrexed with carboplatin or cisplatin, or gemcitabine with cisplatin) versus placebo (an inactive substance that looks like study drug atezolizumab but has no active ingredient) plus chemotherapy in patients with resectable NSCLC to find out which is better.
Clinical Study Identifier: s18-01420
ClinicalTrials.gov Identifier: NCT03456063
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
